Fosamax Exposure and Osteonecrosis of the Jaw: Understanding the Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Inquiry

The legacy of general health and science information dissemination has long served as a cornerstone for public awareness, offering broad guidance on wellness and disease prevention. In this tradition, medical centers and practitioners have provided accessible knowledge to help individuals make informed decisions about their care. This foundational approach emphasizes the importance of understanding how various factors—from lifestyle choices to therapeutic interventions—can influence overall health outcomes. Building on this heritage, a natural progression involves examining specific exposures that may arise in both clinical and occupational settings. One such area of focus is the relationship between certain pharmaceutical agents and their potential long-term effects on oral health. For instance, bisphosphonate medications, commonly prescribed for bone-related conditions, have been associated with concerns regarding jaw integrity. This connection becomes particularly relevant when considering individuals who may encounter these compounds not only as patients but also through professional environments where handling or manufacturing occurs. Thus, the transition from general health education to a more targeted inquiry into occupational exposure is both logical and necessary. By applying the same rigorous, evidence-informed lens used in broader health communication, we can explore how workplace contact with specific substances might influence risk profiles. This shift does not abandon the legacy of accessible science; rather, it refines the focus to address emerging questions about environmental and occupational determinants of health, ensuring that comprehensive awareness remains the guiding principle.

Bridging to Fosamax and Jaw Health

Building on the foundation of general health education, we now turn to a specific pharmaceutical agent: Fosamax (alendronate). Fosamax is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, and exposed bone in the mandible or maxilla, often following dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on identifying areas of non-healing bone.

Mechanisms Linking Fosamax to Osteonecrosis of the Jaw

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Fosamax inhibits bone resorption by suppressing osteoclast activity, which can lead to reduced bone turnover. In the jawbone, this suppression may impair the normal healing response to microdamage or dental procedures. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate (the active ingredient in Fosamax) have examined effects on jawbone properties, including tissue mineral density and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters jawbone structure and function, potentially increasing vulnerability to ONJ.

Risk Factors and Clinical Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may limit the perceived risk.

Causation and Temporal Considerations

Causation-related considerations for affected patients involve establishing a link between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as the condition improves with drug cessation and recurs with re-exposure. However, ONJ can also occur spontaneously, and other risk factors such as dental procedures, cancer, and concomitant medications may contribute (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Therefore, causation must be assessed on a case-by-case basis, considering the patient's medical history, duration of Fosamax use, and presence of other risk factors. The timeline between exposure and documented harm is variable. Symptoms can develop from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients at low risk for fracture, the prescribing information suggests considering drug discontinuation after 3 to 5 years of use, reflecting uncertainty about optimal duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This recommendation may help mitigate the risk of ONJ over time.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis and other bone conditions. It has been associated with osteonecrosis of the jaw (ONJ), a condition where the jawbone fails to heal after minor trauma, leading to exposed bone. The link is due to Fosamax's mechanism of suppressing bone turnover, which can impair healing in the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation between Fosamax and ONJ established?

Causation is supported by evidence that symptoms often improve after stopping Fosamax and may recur upon rechallenge. However, ONJ can also occur spontaneously or due to other factors, so each case must be evaluated individually, considering the patient's history and other risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.